Analysed EDITAS MEDICINE INC (EDIT:NASDAQ) News Sources
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
14-05-2026
yahoo.com
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
21-05-2026
yahoo.com
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
26-05-2026
yahoo.com
What is the current price of EDITAS MEDICINE INC (EDIT:NASDAQ)?
The current price of EDITAS MEDICINE INC (EDIT:NASDAQ) is $3.57.
EDITAS MEDICINE INC (EDIT:NASDAQ) absolute price change since previous trading day?
The absolute price change of EDITAS MEDICINE INC (EDIT:NASDAQ) since the previous trading day is $0.49.
EDITAS MEDICINE INC (EDIT:NASDAQ) percentage price change since previous trading day?
The percentage price change of EDITAS MEDICINE INC (EDIT:NASDAQ) since the previous trading day is 15.9091%.
What is the most recent average sentiment score for EDITAS MEDICINE INC (EDIT:NASDAQ)?
The most recent average sentiment score for EDITAS MEDICINE INC (EDIT:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for EDITAS MEDICINE INC (EDIT:NASDAQ)?
The most recent sentiment for EDITAS MEDICINE INC (EDIT:NASDAQ) is .
SEC-8K** Filing Available For EDITAS MEDICINE INC (EDIT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.